Last June, Patricia Hart — now 59 years — heard words no one wants to hear: triple-negative invasive ductal carcinoma. Her care team was frank about the danger: This form of breast cancer is ...
Patients with advanced melanoma who received fecal microbiota transplants using healthy donor stool alongside standard immunotherapy survived more than four years, according to final results from an ...
Real-world biomarker testing patterns, first line treatment and drivers of treatment choice in patients with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma in the United States ...
Potential biomarker of PD-L1 expression phenotypes in tumor and immune cells for combined PD-1 and CTLA-4 blockade therapies in advanced NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO ...
The US FDA has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck), a subcutaneous version of the intravenous formulation of Keytruda, for adults and children aged 12 years ...
Barbara Burtness, MD highlights key news in head and neck cancer from ESMO 2025, including CAMORAL, ASPEN-03 & -04, OrigAMI-4 & -05 results.
HCW11-040 expands and activates human peripheral blood lymphocytes (PBMCs) and memory T cells significantly better than pembrolizumab alone. HCW11-040 exhibits significantly better anti-tumor activity ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback